These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15788209)

  • 21. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
    Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
    Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma.
    Shao YY; Lin ZZ; Hsu C; Lee KD; Hsiao CH; Lu YS; Huang CC; Shen YC; Hsu CH; Cheng AL
    Oncology; 2012; 82(1):59-66. PubMed ID: 22310088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
    Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
    Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer.
    Treiber G; Röcken C; Wex T; Malfertheiner P
    Z Gastroenterol; 2007 May; 45(5):369-77. PubMed ID: 17503315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Megestrol treatment in patients with hepatocellular carcinoma.
    Farinati F; Gianni S; De Giorgio M; Fiorentini S
    Br J Cancer; 2001 Nov; 85(10):1606-8. PubMed ID: 11720452
    [No Abstract]   [Full Text] [Related]  

  • 26. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
    Pan DY; Qiao JG; Chen JW; Huo YC; Zhou YK; Shi HA
    Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):211-5. PubMed ID: 14599971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma.
    Shiah HS; Chao Y; Chen LT; Yao TJ; Huang JD; Chang JY; Chen PJ; Chuang TR; Chin YH; Whang-Peng J; Liu TW
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):654-64. PubMed ID: 16520988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.
    Pacheco AV; Rasila K; Lee SJ; Rabinowitz I; Elias L; Lee FC; Verschraegen CF
    Urol Oncol; 2008; 26(6):610-5. PubMed ID: 18367103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
    Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
    Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study.
    Mazzanti R; Giallombardo AL; Mini E; Nobili S; Neri B; Arena U; Pantaleo P; Fabbroni V; Ghilardi M; Gattai R; Bandettini L
    Dig Liver Dis; 2004 Apr; 36(4):278-85. PubMed ID: 15115341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.
    Rabe C; Pilz T; Allgaier HP; Halm U; Strasser C; Wettstein M; Sauerbruch T; Caselmann WH
    Z Gastroenterol; 2002 Jun; 40(6):395-400. PubMed ID: 12055662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis.
    Nakamura M; Nagano H; Marubashi S; Miyamoto A; Takeda Y; Kobayashi S; Wada H; Noda T; Dono K; Umeshita K; Monden M
    Cancer; 2008 Apr; 112(8):1765-71. PubMed ID: 18327806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis].
    Naganuma A; Toyoda M; Hamada T; Hagiwara S; Yanagisawa M; Kosone T; Arai H; Abe T; Takagi H
    Gan To Kagaku Ryoho; 2007 May; 34(5):729-34. PubMed ID: 17496446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma.
    Kanayama M; Nagai H; Sumino Y
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):109-14. PubMed ID: 18979100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
    Chan JK; Manuel MR; Ciaravino G; Cheung MK; Husain A; Teng NN
    Gynecol Oncol; 2006 Dec; 103(3):919-23. PubMed ID: 16828852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of flutamide in the treatment of hepatocellular carcinoma.
    Chao Y; Chan WK; Huang YS; Teng HC; Wang SS; Lui WY; Whang-Peng J; Lee SD
    Cancer; 1996 Feb; 77(4):635-9. PubMed ID: 8616754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Retrospective analysis of clinical results in eight patients with advanced hepatocellular carcinoma with lung metastases treated by TS-1].
    Nagata H; Hatano E; Asechi H; Narita M; Yanagida A; Yasuchika K; Ikai I; Uemoto S
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):233-5. PubMed ID: 17301534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: a retrospective analysis.
    Lee JL; Ryu MH; Chang HM; Kim TW; Lee SS; Sym SJ; Kim MK; Kim KM; Lee JS; Kang YK
    J Gastroenterol Hepatol; 2008 May; 23(5):811-6. PubMed ID: 17995941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hepatocellular carcinoma with cirrhosis: treatment with doxorubicin. Phase II evaluation].
    Barbare JC; Ballet F; Petit J; Poupon R; Darnis F
    Bull Cancer; 1984; 71(5):442-5. PubMed ID: 6084528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
    Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
    Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.